Lafuente A, Rodriguez A, Gibanel R, Lafuente M J, Alonso M, Molina R, Ballesta A, Carretero P
Institute of Public Health, Universitat de Barcelona, Spain.
Anticancer Res. 1998 Sep-Oct;18(5B):3771-2.
GST pi (GSTPl) is overexpressed in bladder cancer and desquamation of the tumour may produce detectable levels of urinary GSTPl which could be used as a marker for the early diagnosis of bladder cancer.
A preliminary study in 27 transitional cell carcinoma (TCC) patients and 20 controls, using an ELISA methodl is presented here.
55.5% of TCC patients were positive for GSTP1, while all control samples were negative. Some of the GSTP1 positive cases also gave positive results for haematuria, which indicates that a limitation of this marker involves the contamination of the urine with erythocyte GSTP1. In 5 cases (18.5%) without haematuria detectable levels of GST pi were found.
Further studies would be required to assess the advantages of this technique over clas sical cytology or as a complement to it, especially in patients in a phase of temporary negative haematuria.
谷胱甘肽 S - 转移酶π（GSTPl）在膀胱癌中过表达，肿瘤的脱落可能会产生可检测水平的尿GSTPl，其可作为膀胱癌早期诊断的标志物。
本文介绍了一项对27例移行细胞癌（TCC）患者和20例对照者采用酶联免疫吸附测定（ELISA）方法进行的初步研究。
55.5%的TCC患者GSTP1呈阳性，而所有对照样本均为阴性。部分GSTP1阳性病例的血尿检测结果也呈阳性，这表明该标志物的一个局限性在于尿液受到红细胞GSTP1的污染。在5例（18.5%）无血尿的病例中发现了可检测水平的GSTπ。
需要进一步研究以评估该技术相对于传统细胞学检查的优势，或作为其补充的优势，特别是在暂时无血尿阶段的患者中。
